论文部分内容阅读
目的:沐舒坦雾化吸入治疗矽肺合并慢性阻塞性肺疾病急性发作临床疗效评价。方法:对对照组进行常规治疗,对观察组进行常规治疗的基础上加用沐舒坦雾化吸入治疗。结果:对照组的40名患者中痊愈的有10名,显效的有5名,有效的有12名,无效的有12名,有效率为67.5%;观察组的40名患者中,痊愈的有30名,显效的有6名,有效的有3名,无效的有1名,有效率为97.5%。观察组的治疗效果明显高于对照组(P<0.05);两组患者住院天数相同,比较无统计学意义(P>0.05),两组患者在咳嗽、咳痰和喘息缓解时间方面,观察组缓解时间明显少于对照组,(P<0.05)。结论:沐舒坦雾化吸入治疗矽肺合并慢性阻塞性肺疾病急性发作对于临床症状能够有效地缓解,加快患者的康复时间,减少了患者的痛苦,值得在临床上推广使用。
AIM: To evaluate the clinical efficacy of mucosolvan inhalation in the treatment of acute exacerbation of silicosis complicated with chronic obstructive pulmonary disease. Methods: The control group of conventional treatment, the observation group on the basis of conventional treatment plus mucosolvan inhalation therapy. Results: Of the 40 patients in the control group, 10 were cured, 5 were markedly effective, 12 were effective, 12 were ineffective, and the effective rate was 67.5%. Among the 40 patients in the observation group, those who recovered were 30, markedly effective 6, effective 3, invalid 1, effective rate was 97.5%. The treatment effect in the observation group was significantly higher than that in the control group (P <0.05). The days of hospitalization in the two groups were the same, with no statistical significance (P> 0.05). The two groups of patients in cough, expectoration and wheezing relief time, The remission time was significantly less than that of the control group (P <0.05). Conclusion: Ambroxol inhalation inhalation treatment of silicosis with acute exacerbation of chronic obstructive pulmonary disease can effectively alleviate the clinical symptoms, accelerate the recovery time of patients and reduce the suffering of patients, which is worth popularizing in clinic.